Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects
NCT02095587
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
24
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatic Impairment
Interventions
DRUG:
IPI-145
Sponsor
SecuraBio